After Novartis's investor day, the spotlight quickly moved to the company's $5 billion buyback plan. CEO Joe Jimenez and his team also unveiled some details--a few, at least--about the company's strategic review.
Now that activist investor Carl Icahn has shown his hand of Hologic shares, the sluggish diagnostic giant is likely to attract some buyout attention, and analysts are split on whether the company should sell itself outright or flip its individual units.
Private equity outfit JLL Partners bet big on contract manufacturing last week with its $2.6 billion deal to combine Dutch Royal DSM with its portfolio CMO Patheon, and the fund's co-founder said the company's not done yet.
Which drugmakers are likely to be the biggest dealmakers of 2014? The direct evidence is trickling in. Sanofi CEO Chris Viehbacher, for instance, says he's looking to spend up to €2 billion on deals next year, or about $2.7 billion.
The Economic Times now says Elder is deep into discussions with Indian drugmaker Torrent Pharma, which is talking about 1,700 crore ($291 million) for its peer.
Orphan drugmaker BioMarin Pharmaceutical may have plenty of would-be adoptive parents before long. In the wake of Shire's $4.2 billion ViroPharma deal and BioMarin's own victory with an FDA advisory panel, Big Pharma companies have more incentive to consider buying out the smaller company, analysts tell Bloomberg.
Cardiac device maker Abiomed surged on The Street over the last month, with eager investors pushing the company's stock price up more than 34% since October. The Massachusetts outfit's continued success growing its heart pump revenue is helping to drive the trend, ripening its desirability as a takeover target.
Slightly less than a year after GlaxoSmithKline and Amicus Therapeutics reported that the first step in their Phase III program for the Fabry disease drug Amigal--or migalastat HCI--had ended in failure, the pharma giant has bowed out of its development collaboration.
Chile's CFR Pharmaceuticals faces one more obstacle in its bid for the South African drugmaker Adcock Ingram. After wooing Adcock for months, the Chilean company now faces stepped-up opposition from selling shareholders.
If you take a big bet on an up-and-coming pharmaceutical maker and you turn out to be right, you should be able to reap some profit from your investment. That's what GlaxoSmithKline ($GSK) intends to do with a third of its stake in Aspen Pharmacare, a fast-growing South African drugmaker that has had a partnership with GSK since 2009.